Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Dow
Colorcon
Mallinckrodt
AstraZeneca

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Patent: 9,775,844

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,775,844
Title:Heterocyclic compounds and uses thereof
Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Inventor(s): Kutok; Jeffery L. (Natick, MA), Winkler; David G. (Arlington, MA), Palombella; Vito J. (Needham, MA), Castro; Alfredo C. (Woburn, MA), Evans; Catherine A. (Somerville, MA), Janardanannair; Somarajannair (Woburn, MA), Lescarbeau; Andre (Somerville, MA), Liu; Tao (Wellesley, MA), Tremblay; Martin R. (Melrose, MA)
Assignee: Infinity Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:14/661,656
Patent Claims:see list of patent claims

Details for Patent 9,775,844

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125554 001 2015-11-23   Start Trial Infinity Pharmaceuticals, Inc. (Cambridge, MA) 2034-03-19 RX Orphan search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 002 2015-03-04   Start Trial Infinity Pharmaceuticals, Inc. (Cambridge, MA) 2034-03-19 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 001 2015-03-04   Start Trial Infinity Pharmaceuticals, Inc. (Cambridge, MA) 2034-03-19 RX search
Merck Sharp Dohme KEYTRUDA pembrolizumab POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER 125514 001 2014-09-04   Start Trial Infinity Pharmaceuticals, Inc. (Cambridge, MA) 2034-03-19 RX search
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Start Trial Infinity Pharmaceuticals, Inc. (Cambridge, MA) 2034-03-19 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Baxter
Dow
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.